Home  |  Contact

UniProtKB/Swiss-Prot P08047: Variant p.Thr737Ala

Transcription factor Sp1
Gene: SP1
Variant information

Variant position:  737
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LB/B
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Threonine (T) to Alanine (A) at position 737 (T737A, p.Thr737Ala).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (T) to small size and hydrophobic (A)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  737
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  785
The length of the canonical sequence.

Location on the sequence:   VALSVGTLPLDSGAGSEGSG  T ATPSALITTNMVAMEAICPE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         VALSVGTLPLDSGAGSEGSGTATPSALITTNMVAMEAICPE

Mouse                         VALSVGTLPLDSGAGSE--GTATPSALITTNMVAMEAICPE

Rat                           VALSVGTLPLDSGAGSEGSGTATPSALITTNMVAMEAICPE

Horse                         -----------------------------------------

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 785 Transcription factor Sp1
Region 619 – 785 VZV IE62-binding
Region 708 – 785 Domain D
Modified residue 739 – 739 Phosphothreonine; by MAPK1, MAPK3 and MAPK8
Mutagenesis 728 – 728 S -> A. Exhibits attenuated endoproteolytic cleavage; when associated with A-732.
Mutagenesis 732 – 732 S -> A. Exhibits attenuated endoproteolytic cleavage; when associated with A-728.
Mutagenesis 739 – 739 T -> A. Abolishes MAPK-mediated phosphorylation. 50% reduction in MAPK1/MAPK3-mediated activity on VEGF promoter, 40% reduction in protein levels during mitosis and no effect on dephosphorylation by PP2A. Greatly reduced MAPK1-mediated activity on VEGF promoter; when associated with A-453. Protein levels during mitosis reduced by 70%; when associated with A-278.
Mutagenesis 739 – 739 T -> D. Increased protein stability during mitosis; when associated with D-278.


Literature citations

No reference for the current variant in UniProtKB/Swiss-Prot.

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.